1 July 2021 in Actas Dermo-Sifiliograficas
Leishmaniasis is a chronic disease caused by flagellate protozoa of the genus Leishmania. It is a global disease, but most cases are seen in South America, the Mediterranean, and some areas of Asia and Africa. The 3 main types of leishmaniasis are cutaneous (the most common), mucocutaneous, and visceral, (the most severe). Visceral leishmaniasis is also known as kala-azar. Leishmaniasis is diagnosed by demonstrating the presence of Leishmania amastigotes in clinical specimens using direct microscopic examination or molecular analysis. Various treatments exist, although the evidence supporting the options available for cutaneous leishmaniasis is weak. Both the classical presentation of leishmaniasis and our management of the disease have changed in recent decades because of acquired immune deficiency caused by conditions such as human immunodeficiency infection or the use of tumor necrosis factor inhibitors.
1 July 2021 in Actas Dermo-Sifiliograficas
Leishmaniasis is a chronic disease caused by flagellate protozoa of the genus Leishmania. It is a global disease, but most cases are seen in South America, the Mediterranean, and some areas of Asia and Africa. The 3 main types of leishmaniasis are cutaneous (the most common), mucocutaneous, and visceral (the most severe). Visceral leishmaniasis is also known as kala-azar. Leishmaniasis is diagnosed by demonstrating the presence of Leishmania amastigotes in clinical specimens using direct microscopic examination or molecular analysis. Various treatments exist, although the evidence supporting the options available for cutaneous leishmaniasis is weak. Both the classical presentation of leishmaniasis and our management of the disease have changed in recent decades because of acquired immune deficiency caused by conditions such as human immunodeficiency infection or the use of tumor necrosis factor inhibitors.
10 February 2023 in Anais Brasileiros de Dermatologia
Since the onset of the COVID-19 outbreak, numerous articles have highlighted a possible link between COVID-19 vaccination or infection and Herpesviridae co-infection or reactivation. The authors conducted an exhaustive literature review on this topic, the results of which are presented individually for each member of the Herpesviridae family: Herpes Simplex Virus (HSV) types-1 (HSV-1) and 2 (HSV-2); Varicella-Zoster Virus (VZV); Epstein-Barr Virus (EBV); Cytomegalovirus (CMV); HHV-6; HHV-7; and HHV-8. These human herpesviruses can serve as prognostic markers for the COVID-19 infection and may even underlie some of the clinical manifestations initially attributed to SARS-CoV-2. In addition to SARS-CoV-2 infection, all corresponding vaccines approved to date in Europe appear capable of inducing herpesvirus reactivation. It is important to consider all viruses of the Herpesviridae family when managing patients infected with or recently vaccinated against COVID-19.
17 September 2020 in Journal of the European Academy of Dermatology and Venereology
8 January 2021 in British Journal of Dermatology
Recently, during the development of COVID‐19 pandemic, several publications have warned of possible cutaneous manifestations in association with this novel coronavirus (SARS‐CoV‐2). In our hospital we have created a multidisciplinary unit with a specific protocol to attend patients with these manifestations. Inclusion criteria consisted of patients who, during the development of the pandemic, were clinically suspected and/or microbiologically confirmed of COVID‐19 and had a recent‐onset skin rash (within the last 4 weeks). All patients underwent biochemistry, hematimetry and serology for parvovirus B19 and for human herpesvirus 6 (HHV‐6), as well as other serologies and a coagulation study according to clinical manifestations. Based on the findings, we also randomly selected 12 hospitalized patients, with similar median age, with COVID‐19 but without cutaneous manifestations, and we requested HHV‐6 serology. The SARS‐CoV‐2 antibody assay was Roche´s Elecsys® Anti‐SARS‐CoV‐2 and the HHV‐6 antibody assay was ELISA‐VIDITEST anti‐HHV‐6 IgM (Vidia®). The protocol was approved by the Aragon Ethical Committee for Clinical Research.
23 January 2021 in Australasian Journal of Dermatology